• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶、尿激酶受体和纤溶酶原激活物抑制剂-1的共表达是培养的肺癌细胞实现最佳侵袭性所必需的。

Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.

作者信息

Liu G, Shuman M A, Cohen R L

机构信息

Cancer Research Institute, University of California, San Francisco.

出版信息

Int J Cancer. 1995 Feb 8;60(4):501-6. doi: 10.1002/ijc.2910600413.

DOI:10.1002/ijc.2910600413
PMID:7829264
Abstract

We investigated the importance of the urokinase (uPA)-plasmin system in fostering invasion of human lung cancer cells through artificial basement membranes composed of Matrigel. Eight cell lines (including 1 small cell and 7 non-small cell lines) were examined. One cell line did not express any components of the urokinase system. Four cell lines had substantial levels of endogenous uPA detectable on their surfaces. Three of these cell lines co-expressed the plasminogen activator inhibitor PAI-1 in addition to uPA. Assays for invasiveness revealed 4 cell lines capable of traversing a Matrigel barrier, including the 3 which co-expressed uPA, PAI-1 and uPA receptor. Surprisingly, the cell line expressing only uPA and uPA receptor displayed no invasive capacity despite levels of secreted uPA more than 20-fold higher than the other cell lines studied. Based on these observations, we hypothesized that both uPA and PAI-1 might be important for invasion by lung tumor cells, at least in vitro. We therefore tested polyclonal antibodies which inhibit uPA and PAI-1 activity for their effects on the highly invasive H292 cell line. After 3 days, invasive capacity was inhibited by antibodies to both uPA and PAI-1 in a dose-dependent manner. The plasmin inhibitor aprotinin reduced H292 cell invasion by 70%. Taken together, our data demonstrate that in cultured human lung cancer cells the uPA-plasmin system is important in promoting invasion into basement membranes and suggest that a critical balance between uPA and PAI-1 is necessary for optimal invasiveness. Our data are consistent with results from recent clinical studies showing that PAI-1 expression in tumor tissue is an adverse prognostic feature.

摘要

我们研究了尿激酶(uPA)-纤溶酶系统在促进人肺癌细胞通过基质胶组成的人工基底膜侵袭过程中的重要性。检测了8种细胞系(包括1种小细胞系和7种非小细胞系)。其中1种细胞系不表达尿激酶系统的任何成分。4种细胞系在其表面可检测到大量内源性uPA。其中3种细胞系除uPA外还共表达纤溶酶原激活物抑制剂PAI-1。侵袭性检测显示有4种细胞系能够穿过基质胶屏障,包括3种共表达uPA、PAI-1和uPA受体的细胞系。令人惊讶的是,仅表达uPA和uPA受体的细胞系尽管分泌的uPA水平比其他研究的细胞系高20多倍,但却没有侵袭能力。基于这些观察结果,我们推测uPA和PAI-1可能对肺肿瘤细胞的侵袭都很重要,至少在体外是这样。因此,我们测试了抑制uPA和PAI-1活性的多克隆抗体对高侵袭性H292细胞系的影响。3天后,uPA和PAI-1抗体均以剂量依赖方式抑制了侵袭能力。纤溶酶抑制剂抑肽酶使H292细胞侵袭减少了70%。综上所述,我们的数据表明,在培养的人肺癌细胞中,uPA-纤溶酶系统在促进向基底膜的侵袭中很重要,并表明uPA和PAI-1之间的关键平衡对于最佳侵袭性是必要的。我们的数据与最近临床研究结果一致,这些结果表明肿瘤组织中PAI-1的表达是一个不良预后特征。

相似文献

1
Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.尿激酶、尿激酶受体和纤溶酶原激活物抑制剂-1的共表达是培养的肺癌细胞实现最佳侵袭性所必需的。
Int J Cancer. 1995 Feb 8;60(4):501-6. doi: 10.1002/ijc.2910600413.
2
Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.三种人乳腺癌细胞系中的尿激酶型纤溶酶原激活与其体外侵袭性相关。
Clin Exp Metastasis. 1996 May;14(3):297-307. doi: 10.1007/BF00053903.
3
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.尿激酶与尿激酶受体:与人膀胱癌细胞系体外侵袭性的关联。
J Natl Cancer Inst. 1997 May 21;89(10):709-17. doi: 10.1093/jnci/89.10.709.
4
Role of activated protein C in facilitating basement membrane invasion by tumor cells.活化蛋白C在促进肿瘤细胞侵袭基底膜中的作用。
Cancer Res. 1994 Jan 1;54(1):261-7.
5
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.肝细胞癌的侵袭和转移与尿激酶型纤溶酶原激活物、其受体及抑制剂的关系
J Cancer Res Clin Oncol. 2000 Nov;126(11):641-6. doi: 10.1007/s004320000146.
6
High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis.尿激酶型纤溶酶原激活物高表达促进胆管癌侵袭和转移。
World J Gastroenterol. 2012 Jan 21;18(3):244-50. doi: 10.3748/wjg.v18.i3.244.
7
Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.整合素玻璃粘连蛋白受体αVβ3对尿激酶型纤溶酶原激活剂/纤溶酶介导的黑色素瘤细胞侵袭的调节作用
Int J Cancer. 2001 Feb 1;91(3):300-8. doi: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1055>3.3.co;2-e.
8
The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.尿激酶相关基因在浅表性和浸润性移行细胞癌中的表达
Int J Oncol. 1998 Jan;12(1):175-80. doi: 10.3892/ijo.12.1.175.
9
Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.尿激酶型纤溶酶原激活剂、其受体及纤溶酶原激活剂抑制剂-1在胃癌细胞中的表达及幽门螺杆菌的作用
Scand J Gastroenterol. 2005 Jul;40(7):783-93. doi: 10.1080/00365520510015665.
10
Evidence of a non-conventional role for the urokinase tripartite complex (uPAR/uPA/PAI-1) in myogenic cell fusion.尿激酶三方复合物(uPAR/uPA/PAI-1)在成肌细胞融合中具有非常规作用的证据。
J Cell Sci. 1997 May;110 ( Pt 9):1083-9. doi: 10.1242/jcs.110.9.1083.

引用本文的文献

1
Suppressing Expression of SERPINE1/PAI1 Through Activation of GPER1 Reduces Progression of Vulvar Carcinoma.通过激活 GPER1 抑制 SERPINE1/PAI1 的表达可降低外阴癌的进展。
Cancer Genomics Proteomics. 2024 Nov-Dec;21(6):566-579. doi: 10.21873/cgp.20473.
2
New immune cell engagers for cancer immunotherapy.用于癌症免疫治疗的新型免疫细胞衔接器。
Nat Rev Immunol. 2024 Jul;24(7):471-486. doi: 10.1038/s41577-023-00982-7. Epub 2024 Jan 25.
3
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours.克服 CAR T 细胞疗法治疗实体瘤的靶内非肿瘤毒性。
Nat Rev Clin Oncol. 2023 Jan;20(1):49-62. doi: 10.1038/s41571-022-00704-3. Epub 2022 Nov 23.
4
SERPINE1 Overexpression Promotes Malignant Progression and Poor Prognosis of Gastric Cancer.丝氨酸蛋白酶抑制剂E1过表达促进胃癌的恶性进展和不良预后。
J Oncol. 2022 Jan 29;2022:2647825. doi: 10.1155/2022/2647825. eCollection 2022.
5
The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.纤溶酶原激活物抑制剂-1 在癌症中的悖论:一种机制上的理解。
Cancer Metastasis Rev. 2019 Sep;38(3):483-492. doi: 10.1007/s10555-019-09806-4.
6
Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis.纤溶酶原激活物抑制剂-1(PAI-1)在子宫内膜异位症中的表达。
PLoS One. 2019 Jul 17;14(7):e0219064. doi: 10.1371/journal.pone.0219064. eCollection 2019.
7
Deficiency of protein-L-isoaspartate (D-aspartate) -methyl-transferase expression under endoplasmic reticulum stress promotes epithelial mesenchymal transition in lung adenocarcinoma.内质网应激下蛋白质-L-异天冬氨酸(D-天冬氨酸)-甲基转移酶表达缺失促进肺腺癌上皮-间质转化。
Oncotarget. 2018 Jan 27;9(17):13287-13300. doi: 10.18632/oncotarget.24324. eCollection 2018 Mar 2.
8
Masked Chimeric Antigen Receptor for Tumor-Specific Activation.用于肿瘤特异性激活的掩蔽嵌合抗原受体
Mol Ther. 2017 Jan 4;25(1):274-284. doi: 10.1016/j.ymthe.2016.10.011.
9
Serpine2, a potential novel target for combating melanoma metastasis.丝氨酸蛋白酶抑制剂2(Serpine2),一种对抗黑色素瘤转移的潜在新靶点。
Am J Transl Res. 2016 May 15;8(5):1985-97. eCollection 2016.
10
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.一种前体抗体药物偶联物的临床前研究,该偶联物旨在选择性靶向表皮生长因子受体(EGFR)过表达的肿瘤,以提高治疗效果。
MAbs. 2016;8(2):405-13. doi: 10.1080/19420862.2015.1127491.